Arca
Skip to content

Diabetes mellitus

Drug research and approvals for diabetes mellitus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 1,967 studies of diabetes mellitus are recruiting on ClinicalTrials.gov, Health Canada has authorized 41 drug trials for it since 2013, FDA has 1 approved and 6 open orphan designations naming it, and the EU has 98 authorised medicines for it.

  • Recruiting worldwide: 1,967
  • Trials authorized in Canada: 41
  • FDA orphan approvals: 1
  • EU medicines: 98

Recruiting Now

Newest start dates first, of 1,967 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 41; search them all in Canada trials
Jun 24, 2026A phase 3, randomized, double-blind extension trial to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants…MARIDEBART CAFRAGLUTIDE (AMG 133)AmgenOngoing
May 12, 2026A randomized, double-blind, parallel-group phase III study to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults…ELECOGLIPRON (AZD5004)AstraZeneca Pharmaceuticals LPOngoing
Mar 17, 2025A phase 3 randomized, double-blind, placebo controlled study to evaluate the efficacy, safety, and tolerability of maridebart cafraglutide in adult…MARIDEBART CAFRAGLUTIDE (AMG 133)AmgenOngoing
Sep 6, 2024A phase IIb randomised, double-blind, placebo-controlled and open-label active comparator study to evaluate the efficacy, safety and tolerability of azd5004 in…AZD5004AstraZeneca Pharmaceuticals LPClosed
Jan 19, 2023A phase 1/2, randomized, double-blind, placebo-controlled, 2-part study of the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of single…ALN-KHK (ALN-1613400)Alnylam PharmaceuticalsClosed
Dec 23, 2022A phase 1/2 study to evaluate the safety, tolerability, and efficacy of vx-264 in subjects with type 1 diabetes mellitusVX-264Vertex PharmaceuticalsOngoing
Oct 14, 2022An open-label, first-in-human safety evaluating the safety, tolerability, and efficacy of vctx211 combination product in subjects with type 1 diabetes mellitus…VCTX211 / TACROLIMUS / THYMOGLOBULINCRISPR THERAPEUTICS AGClosed
Aug 8, 2022A phase 1/2 randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and…ICOVAMENIB (BMF-219)BIOMEA FUSION, INC.Closed
Nov 22, 2019A phase II, randomized, parallel group, dose-finding study of subcutaneously administered bi 456906 for 16 weeks, compared with placebo and open-label…BI 456906BOEHRINGER INGELHEIM (CANADA) LTD LTEEClosed
Jan 14, 2019A phase 3b, randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with…DASIGLUCAGONZealand PharmaPending

FDA Orphan Designations

Approved first, then open designations, newest first
Feb 17, 2012Korlymfor the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2…Corcept Therapeutics, Inc.Approved
Feb 5, 2026recombinant human insulintreatment of neonatal diabetes mellitus (monogenic forms of diabetes mellitus that present in infancy)Hellene Solomon Wan, MD - Induvidual sponsor.Designated
Jan 12, 2017anti-interleukin 21 (NNC0114-0006) in combination with…Treatment of Type I Diabetes Mellitus with residual beta cell function.Novo Nordisk, Inc.Designated
Mar 3, 2015alpha1-proteinase inhibitor (human)Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.Grifols Therapeutics, Inc.Designated
Dec 20, 2013CD40/CD80/CD86 modified autologous dendritic cell therapyTreatment Type 1 diabetes mellitus patients with residual beta cell functionDiaVacs, Inc.Designated
May 30, 2013abataceptTreatment of type 1 diabetes mellitus patients with residual beta cell functionOrban Biotech LLCDesignated
Jul 28, 2011alpha-1 proteinase inhibitor (human)Treatment of patients with recent onset (<15 years)with Type 1A diabetes mellitus with residual beta-cell functionKamada, Ltd.Designated

Medicines Authorised in the EU

Newest first; 15 of 98
Jul 15, 2026Liraglutide STADAliraglutideSTADA Arzneimittel AGEMA ↗
May 6, 2026Bysumloginsulin lispro · biosimilarSandoz GmbHEMA ↗
Apr 27, 2026Dazpardainsulin aspart · biosimilarSandoz GmbHEMA ↗
Jan 9, 2026Ondibtainsulin glargine · biosimilarSandoz GmbHEMA ↗
Jan 8, 2026TeizeildteplizumabSanofi Winthrop IndustrieEMA ↗
Nov 24, 2025Kyinsuinsulin icodec;semaglutideNovo Nordisk A/SEMA ↗
Jul 24, 2024ZegaloguedasiglucagonZealand Pharma A/SEMA ↗
May 17, 2024Awiqliinsulin icodecNovo Nordisk A/SEMA ↗
Mar 31, 2023Sitagliptin / Metformin hydrochloride Sunsitagliptin;metformin hydrochloride · genericSun Pharmaceutical Industries Europe B.V.EMA ↗
Mar 24, 2023Dapagliflozin Viatrisdapagliflozin · genericViatris LimitedEMA ↗
Sep 15, 2022MounjarotirzepatideEli Lilly Nederland B.V.EMA ↗
Apr 25, 2022Sitagliptin Accordsitagliptin · genericAccord Healthcare S.L.U.EMA ↗
Mar 24, 2022Vildagliptin / Metformin hydrochloride Accordvildagliptin;metformin hydrochloride · genericAccord Healthcare S.L.U.EMA ↗
Feb 16, 2022Sitagliptin / Metformin hydrochloride Mylansitagliptin hydrochloride monohydrate;metformin hydrochloride · genericMylan Pharmaceuticals LimitedEMA ↗
Dec 9, 2021Sitagliptin SUNsitagliptin fumarate · genericSun Pharmaceutical Industries Europe B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.